Literature DB >> 9118470

Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.

M Looby1, R Linke, M Weiss.   

Abstract

A three-compartment model was fitted to idarubicin data in a NONMEM pooled-data approach. Clearance (CL) of 221.7 ml/min was relatively high, and drug distribution was rapid (CLD = 248.3 ml/min) and extensive [steady-state volume of distribution (Vss) 24 1]. The area under the concentration-time curve (AUC) of idarbicinol was 8 times that of idarubicin. Concentrations of idarubicin (idarubicinol) measured in the myocardium at 24 h after i.v. administration of idarubicin were 20 (5) times those determined in plasma. Tissue concentrations of idarubicinol were up to 400 times those of idarubicin, indicating that the active metabolite contributes significantly to the overall drug action.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9118470     DOI: 10.1007/s002800050614

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  3 in total

1.  Pharmacokinetics and toxicity of idarubicin in the rat.

Authors:  O Kuhlmann; S Hofmann; M Weiss
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

2.  Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin.

Authors:  Mathieu Boulin; Antonin Schmitt; Elisabeth Delhom; Jean-Pierre Cercueil; Maëva Wendremaire; Diane-Charlotte Imbs; Audrey Fohlen; Fabrizio Panaro; Astrid Herrero; Alban Denys; Boris Guiu
Journal:  Eur Radiol       Date:  2015-06-11       Impact factor: 5.315

3.  Caffeine enhances myocardial uptake of idarubicin but reverses its negative inotropic effect.

Authors:  Wonku Kang; Michael Weiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-23       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.